Company Profile

Monoclonal antibodies are an effective and rapidly growing class of drugs while also being a critical research tool essential for the development of many new diagnostics. Established in 2017 around the objective simplifying and streamlining the purification of biotherapeutics to improve global access to these important drugs, Isolere Bio has been structured around development of novel, non-chromatographic technologies for the purification of biologics such as antibodies, gene delivery vectors and personalized cell therapies. In February 2023 it was announced that Donaldson Company, Inc. (NYSE: DCI) - a leading worldwide provider of innovative filtration products and solutions - had acquired Isolere Bio, Inc. (Isolere), an early-stage biotechnology company that develops novel and proprietary IsoTag™ reagents and accompanying filtration processes used for the purification and streamlined manufacturing of biopharmaceuticals. Aimed initially at the purification of viral vectors used for cell and gene therapies, IsoTag™ reagents are designed to substantially improve product quality and purity with faster timelines compared to competing solutions, enabling accelerated and more affordable delivery of life-changing therapies to patients globally. “With the integral addition of Isolere to our Life Sciences portfolio, Donaldson is positioned to create premier separation and filtration solutions for emerging genetic-based drugs,” said Tod Carpenter, chairman, president and chief executive officer of Donaldson. “We look forward to accelerating Isolere’s growth trajectory through sales synergies from our recent acquisitions of Solaris Biotechnology and Purilogics and through the strength of our balance sheet.” “Isolere is thrilled to join the Donaldson family and bring our novel affinity-phase separation technology to market,” said Kelli Luginbuhl, Ph.D, co-founder and chief executive officer of Isolere. “Our technology, complemented by Donaldson’s filtration excellence, is part of a larger vision to bring end-to-end solutions to the life sciences industry.”